EDMONTON, AB, June 8 /PRNewswire-FirstCall/ -- Isotechnika Inc. today announced that the Company has formalized a manufacturing agreement with Lonza Ltd. in Switzerland.
Under the terms of the agreement, Lonza Ltd. will manufacture, in a GMP environment, sufficient quantities of trans-ISA247 for use in the Company's upcoming clinical trials.
"We are pleased to enter into a contractual relationship with Lonza, a company with an international reputation as one of the premier pharmaceutical manufactures," commented Dr. Randall Yatscoff, Isotechnika's President and COO. "This agreement facilitates the Company meeting this years' drug development timelines in a cost-effective and quality controlled manner," added Yatscoff.
"We are very pleased to have reached this agreement with Isotechnika. Based on our technology platform and our experience we are able to support Isotechnika with the required product quantities from clinical trials through to commercial supply," commented Dr. Lukas Utiger, Lonza's Head of Exclusive Synthesis.
This press release may contain forward-looking statements. Forward looking statements, including the Company's belief as to the potential of its products, the Company's expectations regarding the issuance of additional patents and the Company's ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company's patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company's quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.
About Isotechnika Inc.
Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Its entrepreneurial management and world-class team of scientists are building a pipeline of immunosuppressive drug candidates for use in the prevention of organ rejection in transplantation and in the treatment of autoimmune diseases. Isotechnika looks to become the leader in development of immunosuppressant therapies.
Isotechnika's lead drug, ISA247, is an immunosuppressant that has successfully completed a Phase II trial for psoriasis and Phase IIa trial for kidney transplantation. Isotechnika recently expanded its product pipeline by developing two additional novel immunosuppressive compounds, TAFA-93 and TKB662. TAFA-93 is a novel, small molecule mTOR inhibitor, a class of drugs currently used in the prevention of organ rejection in transplantation and as a coated stent therapy in the treatment of coronary artery disease. Pre-clinical studies of TKB662 have demonstrated inhibition of T cell and B cell activation and proliferation through multiple mechanisms of action including the inhibition of lymphocyte phosphorylation activity. As both TAFA-93 and TKB662 have distinct mechanisms of action from calcineurin inhibitors such as ISA247 they have the potential to be administered as complementary therapies in both prevention of organ rejection and treatment of autoimmune diseases. Isotechnika Inc. is an S&P/TSX Composite Index company publicly traded under the symbol ISA. More information on Isotechnika can be found at http://www.isotechnika.com/.
About Lonza Ltd.
Lonza is a life sciences driven company, headquartered in Switzerland, which generated sales of CHF 2.24 billion in 2003. It operates 18 production and R&D facilities in eight countries and employs 5660 people worldwide. Lonza is one of the leading custom manufacturers of chemical intermediates and active ingredients as well as biopharmaceuticals for the pharmaceutical and agrochemical industries. In addition, Lonza also offers organic intermediates for a wide range of applications and provides antimicrobial and associated products as well as polymer intermediates and compounds. For more information please visit the company's website at http://www.lonza.com/.
CONTACT: Dr. Randall Yatscoff, President and COO, Isotechnika Inc.,Phone: (780) 487-1600 extension 246, Fax: (780) 484-4105,E-mail: email@example.com; Stephanie Gillis-Paulgaard, Manager,Corporate Communications, Isotechnika Inc., Phone: (780) 487-1600 extension243, Fax: (780) 484-4105, E-mail: firstname.lastname@example.org;To request a free copy of this organization's annual report, please go tohttp://www.newswire.ca/ and click on reports@cnw.